Lilly’s Multi-Tumor Treatment Retsevmo Closer To EU Approval

Set For First-In-Class Status

 
• By Andrew McConaghie
  
Eli Lilly
Retevmo has another RET-targeting drug hot on its heels, Roche and Blueprint's Gavreto, which gained US approval in September.

More from Business

More from Scrip